Details for Patent: 10,143,680

Which drugs does patent 10,143,680 protect, and when does it expire?

Patent 10,143,680 protects ISTURISA and is included in one NDA.

This patent has thirty-five patent family members in twenty-eight countries.

Summary for Patent: 10,143,680

Title:	Pharmaceutical dosage forms
Abstract:	The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.
Inventor(s):	Beato; Stefania (Basel, CH), Quinton; Peggy (Waldighoffen, FR)
Assignee:	Novartis AG (Basel, CH)
Application Number:	15/323,991
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Process; Dosage form;

Drugs Protected by US Patent 10,143,680

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-001	Mar 6, 2020		RX	Yes	No			Y
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-002	Mar 6, 2020		RX	Yes	No			Y
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-003	Mar 6, 2020		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 10,143,680

PCT Information
PCT Filed	July 06, 2015	PCT Application Number:	PCT/IB2015/055098
PCT Publication Date:	January 14, 2016	PCT Publication Number:	WO2016/005880

International Family Members for US Patent 10,143,680

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	101116
Australia	2015287336
Brazil	112016030243
Canada	2954393
Chile	2017000026